$NSPR
InspireMD, Inc. Stock $nspr

$nspr Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017317 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$1.649M	$1.239M	$1.183M
YoY Change	7.71%	4.73%	17.59%
Cost Of Revenue	$1.158M	$866.0K	$1.061M
YoY Change	5.27%	-18.38%	17.89%
Gross Profit	$491.0K	$373.0K	$122.0K
YoY Change	13.92%	205.74%	15.09%
Gross Profit Margin	29.78%	30.1%	10.31%
Selling, General & Admin	$3.813M	$2.911M	$2.928M
YoY Change	24.77%	-0.58%	13.44%
% of Gross Profit	776.58%	780.43%	2400.0%
Research & Development	$1.993M	$1.843M	$1.680M
YoY Change	-3.06%	9.7%	100.24%
% of Gross Profit	405.91%	494.1%	1377.05%
Depreciation & Amortization	$58.00K	$55.00K	$41.00K
YoY Change	34.88%	34.15%	-19.61%
% of Gross Profit	11.81%	14.75%	33.61%
Operating Expenses	$5.806M	$4.754M	$4.608M
YoY Change	13.58%	3.17%	34.74%
Operating Profit	-$5.315M	-$4.381M	-$4.486M
YoY Change	13.54%	-2.34%	35.37%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$238.0K	$125.0K	$5.000K
YoY Change	428.89%	2400.0%	-92.96%
Pretax Income	-$5.077M	-$4.256M	-$4.481M
YoY Change	9.51%	-5.02%	38.17%
Income Tax
% Of Pretax Income
Net Earnings	-$5.077M	-$4.256M	-$4.481M
YoY Change	9.51%	-5.02%	38.17%
Net Earnings / Revenue	-307.88%	-343.5%	-378.78%
Basic Earnings Per Share	-$0.24	-$0.53	-$0.57
Diluted Earnings Per Share	-$0.24	-$0.53	-$574.2K
COMMON SHARES
Basic Shares Outstanding	8.356M shares	8.327M shares	7.804M shares
Diluted Shares Outstanding	21.07M shares	8.093M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.99M	$12.89M	$29.85M
YoY Change	77.53%	-56.84%	-32.21%
Cash & Equivalents	$11.55M	$4.228M	$7.798M
Short-Term Investments	$35.45M	$8.657M	$22.05M
Other Short-Term Assets	$56.00K	$394.0K	$291.0K
YoY Change	-74.66%	35.4%	40.58%
Inventory	$1.689M	$1.697M	$1.286M
Prepaid Expenses	$56.00K	$394.0K
Receivables	$1.470M	$1.417M	$1.113M
Other Receivables	$312.0K	$310.0K	$91.00K
Total Short-Term Assets	$50.52M	$16.70M	$32.63M
YoY Change	71.25%	-48.81%	-29.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.261M	$887.0K	$1.624M
YoY Change	223.0%	-45.38%	-2.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$857.0K	$859.0K	$915.0K
YoY Change	0.94%	-6.12%	26.56%
Total Long-Term Assets	$3.118M	$3.218M	$2.539M
YoY Change	-4.53%	26.74%	6.46%
TOTAL ASSETS
Total Short-Term Assets	$50.52M	$16.70M	$32.63M
Total Long-Term Assets	$3.118M	$3.218M	$2.539M
Total Assets	$53.64M	$19.92M	$35.17M
YoY Change	63.7%	-43.36%	-27.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.829M	$607.0K	$900.0K
YoY Change	328.48%	-32.56%	124.44%
Accrued Expenses	$742.0K	$933.0K	$2.696M
YoY Change	-52.53%	-65.39%	15.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.829M	$4.383M	$3.691M
YoY Change	2.48%	18.75%	28.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.996M	$2.112M	$1.776M
YoY Change	-13.67%	18.92%	-2.15%
Total Long-Term Liabilities	$1.996M	$2.112M	$1.776M
YoY Change	-13.67%	18.92%	-2.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.829M	$4.383M	$3.691M
Total Long-Term Liabilities	$1.996M	$2.112M	$1.776M
Total Liabilities	$6.825M	$6.495M	$5.467M
YoY Change	-2.83%	18.8%	16.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$210.9M	-$205.8M
YoY Change	9.73%
Common Stock	$2.000K	$1.000K
YoY Change	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$46.81M	$13.43M	$29.70M
YoY Change
Total Liabilities & Shareholders Equity	$53.64M	$19.92M	$35.17M
YoY Change	63.7%	-43.36%	-27.68%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$5.077M	-$4.256M	-$4.481M
YoY Change	9.51%	-5.02%	38.17%
Depreciation, Depletion And Amortization	$58.00K	$55.00K	$41.00K
YoY Change	34.88%	34.15%	-19.61%
Cash From Operating Activities	-$3.325M	-$4.831M	-$4.152M
YoY Change	7.57%	16.35%	14.03%
INVESTING ACTIVITIES
Capital Expenditures	$45.00K	$25.00K	-$37.00K
YoY Change	-139.13%	-167.57%	42.31%
Acquisitions
YoY Change
Other Investing Activities	-$26.85M	$4.474M	-$10.00K
YoY Change	-1467.6%	-44840.0%	-600.0%
Cash From Investing Activities	-$26.89M	$4.449M	-$47.00K
YoY Change	-1555.14%	-9565.96%	95.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	37.53M
YoY Change	-101543.24%
NET CHANGE
Cash From Operating Activities	-3.325M	-$4.831M	-4.152M
Cash From Investing Activities	-26.89M	$4.449M	-47.00K
Cash From Financing Activities	37.53M
Net Change In Cash	7.318M	-$404.0K	$0.00
YoY Change	-671.72%		-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$3.325M	-$4.831M	-$4.152M
Capital Expenditures	$45.00K	$25.00K	-$37.00K
Free Cash Flow	-$3.370M	-$4.856M	-$4.115M
YoY Change	13.24%	18.01%	13.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001433607
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001433607
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	887000	usd
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-35731
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	InspireMD, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2123838
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4 Menorat Hamaor St.
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Tel Aviv
CY2023Q1	dei	Entity Address Country EntityAddressCountry	IL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6744832
CY2023Q1	dei	City Area Code CityAreaCode	(888)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	776-6204
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	NSPR
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8356394	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4228000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4632000	usd
CY2023Q1	NSPR	Shortterm Bank Deposits ShorttermBankDeposits	8657000	usd
CY2022Q4	NSPR	Shortterm Bank Deposits ShorttermBankDeposits	13171000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1417000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1034000	usd
CY2023Q1	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	310000	usd
CY2022Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	213000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	394000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	655000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1697000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1621000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	16703000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	21326000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	746000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	917000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1472000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1554000	usd
CY2023Q1	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	859000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	856000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	3218000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3327000	usd
CY2023Q1	us-gaap	Assets Assets	19921000	usd
CY2022Q4	us-gaap	Assets Assets	24653000	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	607000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	659000	usd
CY2023Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	3776000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4411000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4383000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5070000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1081000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1195000	usd
CY2023Q1	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1031000	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	995000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2112000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2190000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	6495000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7260000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8326648	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8326648	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8330918	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8330918	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	219266000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	218977000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-205841000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201585000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13426000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17393000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19921000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24653000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1239000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1183000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	866000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1061000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	373000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	122000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1843000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1680000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	788000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2123000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2182000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4754000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	4608000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4381000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4486000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	125000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4256000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4481000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8093340	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7804245	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	33532000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4481000	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	4563	shares
CY2022Q1	NSPR	Sharebased Compensation Related To Restricted Stock And Stock Options Award Net Of Forfeitures Of Shares SharebasedCompensationRelatedToRestrictedStockAndStockOptionsAwardNetOfForfeituresOfShares	653000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	29704000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17393000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17393000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4256000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	4270	shares
CY2023Q1	NSPR	Sharebased Compensation Related To Restricted Stock And Stock Options Award Net Of Forfeitures Of Shares SharebasedCompensationRelatedToRestrictedStockAndStockOptionsAwardNetOfForfeituresOfShares	289000	usd
CY2023Q1	NSPR	Sharebased Compensation Related To Restricted Stock And Stock Options Award Net Of Forfeitures Of Shares SharebasedCompensationRelatedToRestrictedStockAndStockOptionsAwardNetOfForfeituresOfShares	289000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13426000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13426000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4256000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4481000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	55000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	41000	usd
CY2023Q1	us-gaap	Defined Benefit Plan Settlements Benefit Obligation DefinedBenefitPlanSettlementsBenefitObligation	36000	usd
CY2022Q1	us-gaap	Defined Benefit Plan Settlements Benefit Obligation DefinedBenefitPlanSettlementsBenefitObligation	46000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-22000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-7000	usd
CY2023Q1	NSPR	Change In Right Of Use Asset And Leasing Liability ChangeInRightOfUseAssetAndLeasingLiability	34000	usd
CY2022Q1	NSPR	Change In Right Of Use Asset And Leasing Liability ChangeInRightOfUseAssetAndLeasingLiability	25000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	289000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	653000	usd
CY2023Q1	NSPR	Loss Gains On Amounts Funded In Respect Of Employee Rights Upon Retirement Net LossGainsOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet	23000	usd
CY2022Q1	NSPR	Loss Gains On Amounts Funded In Respect Of Employee Rights Upon Retirement Net LossGainsOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet	18000	usd
CY2023Q1	NSPR	Interest Income From Shortterm Bank Deposits InterestIncomeFromShorttermBankDeposits	-14000	usd
CY2022Q1	NSPR	Interest Income From Shortterm Bank Deposits InterestIncomeFromShorttermBankDeposits	17000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-261000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-231000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	383000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-111000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	97000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-74000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	76000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	143000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-52000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	7000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-633000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-656000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4831000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4134000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2500000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	6000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	7000000	usd
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	6000000	usd
CY2023Q1	NSPR	Amounts Withdrawn In Respect Of Employee Rights Upon Retirement Net AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet	26000	usd
CY2022Q1	NSPR	Amounts Withdrawn In Respect Of Employee Rights Upon Retirement Net AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet	28000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4449000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-65000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-22000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-7000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-404000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4206000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4632000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12004000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4228000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7798000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zboRiqJQ4Eg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_821_zqmIFncsj8fa">DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s MGuard™ Prime™ embolic protection system (“MGuard Prime EPS”) was marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions, or bypass surgery. MGuard Prime EPS combines MicroNet with a bare-metal cobalt-chromium based stent. MGuard Prime EPS received CE mark approval in the European Union in October 2010 for improving luminal diameter and providing embolic protection. Over the past years, there has been a shift in industry preferences away from bare-metal stents, such as MGuard Prime EPS in ST-Elevation Myocardial Infarction (“STEMI”) patients. As a result of declining sales of the MGuard Prime EPS, which the Company believes is largely driven by the predominant industry preferences favoring drug-eluting, or drug-coated, stents, during the second quarter of 2022, the Company ceased sales of the Company’s MGuard Prime EPS following a phase out period.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company markets its products through distributors in international markets, mainly in Europe.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an accumulated deficit as of March 31, 2023, as well as a history of net losses and negative operating cash flows in recent years. The Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. As a result of these expected losses and negative cash flows from operations, along with the Company’s current cash position, the Company has sufficient resources to fund operations until the end of September 2023. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s plans include the continued commercialization of the Company’s product and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce activities, curtail or cease operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 12, 2023, the Company entered into a securities purchase agreement for the issuance and sale of Company securities in a private placement. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate gross proceeds to the Company in respect of the private placement is expected to be approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20230511__20230512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaQThNHS6KN7" title="Private placement">42.2</span> million, before deducting fees payable to the placement agent and other offering expenses payable by the Company and before exercising any warrants. The offering is expected to close on or about May 15, 2023, subject to the satisfaction of customary closing conditions. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Failure to satisfy regulatory requirements of the new European Medical Device Regulation could prevent the Company from marketing CGuard EPS in countries requiring the CE Mark.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the European Union nations, medical devices must obtain a CE mark before they may be placed on the market. In order to obtain and maintain the CE mark, the Company must Company with EU law on medical devices, which, until May 26, 2021 was governed by the MDD, by presenting comprehensive technical files for the Company’s products demonstrating safety and efficacy of the product to be placed on the market and passing initial and annual quality management system audit as per ISO 13485 standard by a European Notified Body. The company has obtained ISO 13485 quality system certification and CGuard EPS that the Company currently distribute into the European Union, displays the required CE mark. In order to maintain certification, the Company is required to pass an annual surveillance audit conducted by Notified Body auditors. The European Union replaced the MDD with the new MDR regulations. The MDR entered into force after a transitional period of three years and a one year extension of that transition period due to the COVID-19 pandemic on May 26, 2021 and which changes several aspects of the regulatory framework in the European Union. Manufacturers had the duration of the transition period to update their technical documentation and processes to meet the new requirements in order to obtain a CE Mark. In the Company’s specific case, the Company’s CE mark for CGuard EPS under the MDD expired on November 12, 2022, and the Company is in the final stages of technical documentation review by the Notified Body auditor to meet the MDR requirements for recertification. In the meantime, on February 14, 2023, the Company received a derogation per Article 97 paragraph 1 of Regulation 2017/745 from the Agency for Medicines and Health Products (FAMHP) allowing the Company to continue marketing CGuard EPS in the EU until August 15, 2023, subject to certain procedural requirements. Subsequently, on March 20, 2023 Regulation (EU) 2023/607 was published allowing the Company to continue marketing CGuard EPS in EU countries under the MDD directive until December 31, 2027. As a result of the foregoing, the Company may market and sell CGuard EPS in the EU and certain other jurisdictions subject to certain procedural requirements while the Company’s MDR CE recertification is pending.</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to the Geopolitical and Military Tensions Between Russia and Ukraine in Europe</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, Russia launched a military invasion into Ukraine. The Company derived approximately 12.1% of total sales in Russia and Belarus in 2022 while during the three months ended March 31, 2023 and March 31,2022, The Company’s sales to Russia and Belarus were 7.9% and 1.5% respectively. The escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble could negatively impact the Company’s operations, sales, and future growth prospects in that region.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the crisis in Ukraine, the United States and the EU have implemented sanctions against certain Russian individuals and entities and have made it more difficult for the Company to collect on outstanding accounts receivable from customers in this region. The Company’s global operations expose the Company to risks that could adversely affect the Company’s business, financial condition, results of operations, cash flows or the market price of the Company’s securities, including the potential for increased tensions between the United States and Russia resulting from the current situation involving Russia and Ukraine, tariffs, economic sanctions and import-export restrictions imposed by either nation, and retaliatory actions by the other nation, as well as the potential negative impact on the Company’s business and sales in Russia, and Belarus. Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S. government against certain companies and individuals may hinder the Company’s ability to conduct business with potential or existing customers and vendors in these countries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. government has imposed sanctions through several executive orders restricting U.S. companies from conducting business with specified Russian individuals and companies. While the Company believes that the executive orders currently do not preclude the Company from conducting business with the Company’s current customers or vendors in Russia, and Belarus, the sanctions imposed by the U.S. government may be expanded in the future to restrict the Company from engaging with them. If the Company is unable to conduct business with new or existing customers or vendors or pursue business opportunities in Russia, or Belarus, the Company’s business, including revenue, profitability and cash flows, and operations could be adversely affected. The Company cannot provide assurance that current sanctions or potential future changes in sanctions will not have a material impact on the Company’s operations in Russia, and Belarus or on the Company’s financial results.</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_808_eus-gaap--BasisOfAccounting_z2OTnFICU8t5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_829_zBapmg9ZwAr2">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of the Company, the financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2023 and its results of operations, changes in equity and cash flows for the three months ended March 31, 2023 and 2022. These consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022, as found in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 30, 2023. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of results that could be expected for the entire fiscal year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2773675	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2903634	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1793504000	shares
CY2023Q1	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	155000000	shares
CY2023Q1	NSPR	Capital Stock Par Or Stated Value Per Share CapitalStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	45,000 options are subject to a three-year vesting period (of which 20,000 options are vesting in the first year, 15,000 options are vesting in the second year and 10,000 options are vesting in the third year) and 5,000 options with performance conditions related to marketing activities.
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.2458	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.2561	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0365	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0368	pure
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	138000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	179000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	690000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	510000	usd
CY2023Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	869000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	932000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1697000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1621000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	970000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1853000	usd
CY2023Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	240000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	197000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	933000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	554000	usd
CY2023Q1	NSPR	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	1046000	usd
CY2022Q4	NSPR	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	1258000	usd
CY2023Q1	NSPR	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	417000	usd
CY2022Q4	NSPR	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	419000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	170000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	130000	usd
CY2023Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	3776000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4411000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1239000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1183000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1239000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1183000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-017317-index-headers.html	Edgar Link	pending
0001493152-23-017317-index.html	Edgar Link	pending
0001493152-23-017317.txt	Edgar Link	pending
0001493152-23-017317-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nspr-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
nspr-20230331_cal.xml	Edgar Link	unprocessable
nspr-20230331_def.xml	Edgar Link	unprocessable
nspr-20230331_lab.xml	Edgar Link	unprocessable
nspr-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NSPR
InspireMD, Inc. Stock $nspr

2023 Q2 Form 10-Q Financial Statement

#000149315223017317 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NSPR InspireMD, Inc. Stock $nspr

2023 Q2 Form 10-Q Financial Statement

#000149315223017317 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NSPR
InspireMD, Inc. Stock $nspr